Imx-110 for Breast Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Breast Cancer+4 MoreImx-110 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is designed to assess the safety and tolerability of a new drug, IMX-110, with the goal of finding the recommended dose for further study.

Eligible Conditions
  • Pancreatic Cancer
  • Breast Cancer
  • Advanced Solid Tumors
  • Ovarian Cancer
  • Solid Tumors, Adult

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

3 Primary · 5 Secondary · Reporting Duration: 5 years

28 days
Maximum tolerated dose (MTD) of IMX-110 in patients with advanced solid tumors for evaluation in Phase 2a.
Number of participants with treatment-related adverse events assessed by CTCAE v4.03.
Recommended Phase 2 Dose (RP2D) of IMX-110 in patients with advanced solid tumors
5 days
Plasma concentrations of IMX-110
5 years
Duration of Response (DOR)
Overall Survival (OS)
Progression-free survival (PFS)
8 weeks
Response Rate
Day 28
Pharmacodynamic activity of IMX-110 with appropriate biomarkers.

Trial Safety

Safety Progress

1 of 3

Similar Trials

Trial Design

1 Treatment Group

Imx-110
1 of 1

Experimental Treatment

70 Total Participants · 1 Treatment Group

Primary Treatment: Imx-110 · No Placebo Group · Phase 1 & 2

Imx-110
Drug
Experimental Group · 1 Intervention: Imx-110 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years

Who is running the clinical trial?

Immix Biopharma Australia Pty LtdLead Sponsor

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: